Passage Bio (PASG) Stock Price, News & Analysis

Company Overview

Passage Bio is a clinical-stage biotechnology company focused on the development of gene therapies to treat rare, monogenic central nervous system and neuromuscular disorders. The company applies its in-house gene therapy platform to design and engineer adeno-associated virus (AAV)–based vectors that restore or replace defective genes, aiming to deliver durable treatments with a single administration.

The company’s lead programs include PBGM01, an AAV9-based therapy for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), which is conducting a first-in-human study to assess safety and potential therapeutic benefit. Passage Bio is also advancing PBFT02, an AAV-based gene therapy targeting progranulin deficiency in frontotemporal dementia linked to GRN mutations, and PBCH10 for achromatopsia, a rare inherited form of color blindness. Each program is designed to address significant unmet needs in genetically defined patient populations.

Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Passage Bio emerged from collaborations with academic and research institutions specializing in gene therapy and neurology. The company completed its initial public offering in 2020 to support clinical development and expand manufacturing capabilities. Its leadership team is led by President and Chief Executive Officer David Meeker, who brings extensive experience in biotechnology and rare disease drug development.

Passage Bio conducts its clinical and preclinical activities primarily in the United States and collaborates with international research centers to facilitate patient access and data collection. The company is committed to advancing transformational therapies for patients with severe genetic disorders and strengthening its vector manufacturing infrastructure to ensure scalable and compliant production.

Key Stats

• Today's Range: $4.19 to $5.00
• 50-Day Range: $4.08 to $11.68
• 52-Week Range: $3.29 to $20.00
• Volume: 279,266 shs
• Average Volume: 128,647 shs
• Market Capitalization: $15.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.25
• Consensus Rating: Hold

Passage Bio Stock Analysis - MarketRank™

Passage Bio scored higher than 79% of companies evaluated by MarketBeat, and ranked 139th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

Passage Bio has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on no strong buy ratings, 2 buy ratings, 6 hold ratings, and 1 sell rating.

Upside Potential

Passage Bio has a consensus price target of $13.25, representing about 181.9% upside from its current price of $4.70.

Amount of Analyst Coverage

Passage Bio has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Passage Bio are expected to decrease in the coming year, from ($8.62) to ($8.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Passage Bio is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Passage Bio is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Passage Bio has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.03% of the float of Passage Bio has been sold short.

Short Interest Ratio / Days to Cover

Passage Bio has a short interest ratio ("days to cover") of 2.56, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Passage Bio has recently decreased by 24.10%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Passage Bio does not currently pay a dividend.

Dividend Growth

Passage Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.45

News Sentiment

Passage Bio has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Passage Bio this week, compared to 1 article on an average week.

MarketBeat Follows

2 people have added Passage Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Passage Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.90% of the stock of Passage Bio is held by insiders.

Percentage Held by Institutions

53.48% of the stock of Passage Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 6/28/2026
• Next Earnings (Estimated): 7/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PASG
• CIK: 1787297
• Web: www.passagebio.com
• Phone: 267-866-0311
• Fax: N/A
• Employees: 130
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Passage Bio: $13.25
• High Price Target: $23.00
• Low Price Target: $7.00
• Potential Upside/Downside: +181.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.52 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -150.88%
• Return on Assets: -59.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.73
• Quick Ratio: 1.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.90 per share
• Price / Book: 0.80

Miscellaneous

• Outstanding Shares: 3,210,000
• Free Float: 3,051,000
• Market Cap: $15.09 million
• Optionable: No Data
• Beta: 1.41